Bluejay Diagnostics, Inc. BJDX

Company Overview

Bluejay Diagnostics, Inc. is a U.S.-based medical diagnostics company focused on developing rapid, near-patient testing technologies for critical care and acute disease management. The company operates within the in vitro diagnostics and point-of-care testing industries, with an emphasis on diagnostic platforms intended to deliver faster clinical decision-making in hospital and emergency care settings. Its primary focus has been the development of the Symphony platform, a proprietary diagnostic system designed to provide rapid biomarker testing from whole blood samples at or near the point of care.

The company’s principal product development efforts have centered on sepsis and critical care diagnostics, particularly tests intended to identify elevated inflammatory biomarkers associated with severe infection and patient deterioration. Bluejay Diagnostics has positioned itself around reducing turnaround times compared with traditional centralized laboratory testing, aiming to improve triage and treatment speed in intensive care and emergency department environments. The company traces its origins to technologies licensed and developed through collaborations with academic and biomedical partners and later evolved into a publicly traded diagnostics developer listed on Nasdaq under the ticker BJDX.